Antisense Oligonucleotides and RNA Interference - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 375

[94] Xanthos JB, Kofron M, Wylie C, Heasman J. Maternal VegT is the initiator of a molec-
ular network specifying endoderm in Xenopus laevis . Development 2001;128:167-80.
[95] Lima WF, Crooke ST. Cleavage of single strand RNA adjacent to RNA-DNA duplex
regions by Escherichia coli RNase H1. J Biol Chem 1997;272:27513-16.
[96] Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature
2004;431:343-9.
[97] Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient reduction of
target RNAs by small interfering RNA and RNase H-dependent antisense agents. J Biol
Chem 2003;278:7108-18.
[98] Crooke ST. Progress in evaluation of the potential of antisense technology. Antisense
Res Dev 1994;4:145-6.
[99] Crooke ST. Oligonucleotide therapeutics. In: Wolff ME, editor. Burger's medicinal
chemistry and drug discovery, vol. 1. New York, NY: John Wiley; 1995. p. 863-900.
[100] Kurreck J. Antisense technologies: improvement through novel chemical modifications.
Eur J Biochem 2003;270:1628-44.
[101] Miller PS, Yano J, Yano E, Carroll C, Jayaraman K, Ts'o PO. Nonionic nucleic acid
analogues. Synthesis and characterization of dideoxyribonucleoside methylphospho-
nates. Biochemistry 1979;18:5134-43.
[102] Miller PS, Bhan P, Cushman CD, Kean JM, Levis JT. Antisense oligonucleoside meth-
ylphosphonates and their derivatives. Nucleosides Nucleotides Nucleic Acids 1991;10:
37-46.
[103] Tonkinson JL, Stein CA. Patterns of intracellular compartmentalization, trafficking and
acidification of 5-fluorescein labeled phosphodiester and phosphorothioate oligode-
oxynucleotides in HL60 cells. Nucleic Acids Res 1994;22:4268-75.
[104] Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL. Mechanism of cellular uptake
of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic
Acids Res 1991;19:5543-50.
[105] DeClerq E, Eckstein F, Merigan TC. Interferon induction increased through chemical
modification of a synthetic polyribonucleotide. Science 1969;165:1137-9.
[106] Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, et al. Phosphorothioate
analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human
immunodeficiency virus. Proc Natl Acad Sci USA 1987;84:7706-19.
[107] Stein CA, Cohen JS. Phosphorothioate oligodeoxynucleotide analogues. In: Cohen JS,
editor. Oligodeoxynucleotides: antisense inhibitors of gene expression. Boca Raton, FL:
CRC Press; 1989. p. 97-117.
[108] Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleoside phosphorothioate sta-
bility in subcellular extracts, culture media, sera, and cerebrospinal fluid. J Biochem
Biophys Methods 1990;20:259-67.
[109] Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, et al.
Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA
1989;86:3474-8.
[110] Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, et al.
2- O -(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oli-
gonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of
the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.
J Biol Chem 1997;272:11994-20000.
[111] Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA
by strand displacement with a thymine-substituted polyamide. Science 1991;254:
1497-500.